Purpose Of Review: The biology of hairy-cell leukaemia is reviewed, focussing first on the hairy cell itself and then on its interactions with the microenvironment.
Recent Findings: Hairy cells are highly activated clonal B cells related to memory cells, normally resident in the marginal zone of the spleen. Their activation results from multiple stimuli arising from the microenvironment, autocrine cytokines and the still unknown transforming oncogenic event(s) responsible for the disease. Protein kinase Cepsilon is a central player in the activation process.
Summary: The activation of hairy cells makes them unusually sensitive to interferon and nucleosides. Future important research topics include characterization of the oncogenic events responsible for the disease and for its associated differentiation block.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOH.0b013e328338c417 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions.
Expert Rev Hematol
December 2024
CHU Caen Normandie, Avenue Côte de Nacre, Hématologie, Caen cedex, France.
Article Synopsis
- * Differentiating HCL from similar disorders is crucial, as recent advancements in molecular biology and new drug developments (like BRAF and MEK inhibitors) show promise for relapsed cases, alongside ongoing clinical trials.
- * For treating fit patients with HCL or its variant, the combination of Cladribine and rituximab is standard, while BRAF and BTK inhibitors are considered for patients with relapsed conditions; optimal treatment strategies are still being explored. *
Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations.
Innovation (Camb)
November 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing 100142, P.R. China.
Article Synopsis
- * BRAF mutations are common in various cancers, and targeted therapies, especially BRAF inhibitors like dabrafenib and trametinib, are developed for treating solid tumors with these mutations.
- * An expert consensus has been established to improve the diagnosis and treatment of solid tumors with BRAF mutations, focusing on summarizing their clinical features, recommending genetic testing methods, and creating a systematic approach for patient care.
Closing the gap between biology and classification in splenic B-cell lymphomas.
Histopathology
January 2025
Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
The mature splenic B-cell lymphomas are an enigmatic group of lymphoid neoplasms that have long caused significant difficulty for the practicing pathologist due to overlapping diagnostic features among entities and the decreasing availability of splenic tissue for assessment. While some entities have highly characteristic and specific clinicopathological features (e.g.
View Article and Find Full Text PDFDevelopment of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies.
ACS Pharmacol Transl Sci
July 2024
Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, Siena 53100, Italy.
Article Synopsis
- * Among the leukemias, acute myeloid leukemia (AML) is highly aggressive with poor survival rates, especially in patients with specific gene mutations, while hairy cell leukemia (HCL) remains rare and untreated with approved drugs.
- * New epigenetic therapies, particularly histone deacetylase (HDAC) inhibitors, show promise in targeting blood cancers, with new hydroxamic acid derivatives demonstrating effectiveness in inducing cell death and improving outcomes in models of AML and other blood cancers.
Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group.
Cancers (Basel)
June 2024
Hématologie Biologique, Structure Fédérative D'oncogénétique Cyto-Moléculaire du CHU de Caen (SF-MOCAE), CHU de Caen, 14000 Caen, France.
Article Synopsis
- Hairy-cell leukemia (HCL) is a rare blood cancer that has improved prognosis due to treatments like purine nucleoside analogs, but some patients experience relapses and chemotherapy resistance.
- Recent advances in understanding HCL's genetic and cellular mechanisms have led to the development of targeted therapies, including BRAF and MEK inhibitors.
- Updated guidelines emphasize the importance of BRAF mutation for diagnosis, the relevance of certain immunoglobulin mutations for prognosis, and recommend strategies for managing both HCL and similar disorders.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!